First Trust Direct Indexing L.P. Raises Position in IQVIA Holdings Inc. (NYSE:IQV)

First Trust Direct Indexing L.P. raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,299 shares of the medical research company’s stock after buying an additional 243 shares during the quarter. First Trust Direct Indexing L.P.’s holdings in IQVIA were worth $2,352,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in IQV. Los Angeles Capital Management LLC increased its position in shares of IQVIA by 17.5% in the fourth quarter. Los Angeles Capital Management LLC now owns 118,616 shares of the medical research company’s stock worth $27,445,000 after purchasing an additional 17,677 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of IQVIA by 4.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock worth $532,070,000 after buying an additional 93,194 shares during the last quarter. Cadian Capital Management LP purchased a new stake in shares of IQVIA during the 4th quarter valued at $70,108,000. Nomura Holdings Inc. bought a new stake in shares of IQVIA during the 4th quarter worth $857,000. Finally, International Assets Investment Management LLC purchased a new position in IQVIA in the fourth quarter worth $13,759,000. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the subject of several research analyst reports. Robert W. Baird dropped their price target on IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a research note on Friday, May 3rd. The Goldman Sachs Group began coverage on IQVIA in a research report on Thursday, June 6th. They issued a “buy” rating and a $270.00 target price for the company. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, June 29th. Barclays lowered their price objective on shares of IQVIA from $275.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, June 28th. Finally, Evercore ISI decreased their target price on shares of IQVIA from $275.00 to $250.00 and set an “outperform” rating on the stock in a research report on Friday, May 3rd. Three research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $257.73.

IQVIA Trading Down 0.3 %

IQV opened at $206.81 on Friday. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.88. The business has a 50 day simple moving average of $222.16 and a two-hundred day simple moving average of $229.72. The firm has a market capitalization of $37.68 billion, a price-to-earnings ratio of 28.25, a PEG ratio of 1.88 and a beta of 1.49.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.11. The company had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. Analysts predict that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.